Back to top
more

Medtronic (MDT)

(Real Time Quote from BATS)

$91.77 USD

91.77
2,806,120

-0.97 (-1.05%)

Updated Aug 12, 2025 03:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tirthankar Chakraborty headshot

Top Stocks to Invest in America's Aging Workforce

by Tirthankar Chakraborty

Percentage of Americans aged 65 and above will climb to 21% by 2030 from 15% in 2018. In fact, the number of Americans aged more than 60 have already tripled since 1950.

Zacks Equity Research

Boston Scientific Gets a Boost From New Products, Buyouts

by Zacks Equity Research

Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.

Sriparna Ghosal headshot

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

by Sriparna Ghosal

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Zacks Equity Research

Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls

by Zacks Equity Research

Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.

Zacks Equity Research

NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show

by Zacks Equity Research

NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.

Zacks Equity Research

Globus Medical Gains From International Spine Arm, Innovation

by Zacks Equity Research

Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Zacks Equity Research

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Medtronic (MDT) closed at $117.33, marking a +0.25% move from the previous day.

Zacks Equity Research

Boston Scientific Stock Dips on Dull Preliminary Q4 Results

by Zacks Equity Research

Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.

Zacks Equity Research

LabCorp Hits New 52-Week High: What's Driving the Stock?

by Zacks Equity Research

LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.

Zacks Equity Research

Medtronic's Neurostimulator DBS System Receives CE Mark

by Zacks Equity Research

Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.

Zacks Equity Research

UnitedHealth (UNH) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

UnitedHealth's (UNH) Q4 earnings are likely to have benefited from its operating segments and membership growth.

Zacks Equity Research

Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift

by Zacks Equity Research

Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.

Zacks Equity Research

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed at $118.39 in the latest trading session, marking a +1.62% move from the prior day.

Zacks Equity Research

Globus Medical Stock Up on Solid '19 Preliminary Results

by Zacks Equity Research

Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

Zacks Equity Research

Medtronic (MDT) Buys Stimgenics, To Present New Trial Results

by Zacks Equity Research

Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.

Zacks Equity Research

Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod

by Zacks Equity Research

Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.

Zacks Equity Research

Neogen Expands in South America With Productos Acquisition

by Zacks Equity Research

Neogen (NEOG) expands operations in South America by acquiring its food safety diagnostics distributor partner that operates in Argentina and Uruguay.

Zacks Equity Research

Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MDT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.

Zacks Equity Research

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on its stellar segmental performance in Q3.

Zacks Equity Research

Medtronic (MDT) Stock Moves -0.59%: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed at $113.88 in the latest trading session, marking a -0.59% move from the prior day.

Zacks Equity Research

Hill-Rom Hits New 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Hill-Rom (HRC) is optimistic about maintaining its growth momentum on several recent developments.

Zacks Equity Research

Amedisys Completes Asana Hospice Acquisition, Expands Network

by Zacks Equity Research

Amedisys (AMED) closes Asana takeover to strengthen its hospice care network.